Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Change in Accured Expenses: 2022-2025

Historic Change in Accured Expenses for bioAffinity Technologies (BIAF) over the last 4 years, with Sep 2025 value amounting to -$63,487.

  • bioAffinity Technologies' Change in Accured Expenses rose 2.09% to -$63,487 in Q3 2025 from the same period last year, while for Sep 2025 it was $80,295, marking a year-over-year decrease of 69.17%. This contributed to the annual value of $248,911 for FY2024, which is 31.24% down from last year.
  • Per bioAffinity Technologies' latest filing, its Change in Accured Expenses stood at -$63,487 for Q3 2025, which was up 80.33% from -$322,701 recorded in Q2 2025.
  • In the past 5 years, bioAffinity Technologies' Change in Accured Expenses ranged from a high of $506,025 in Q4 2023 and a low of -$322,701 during Q2 2025.
  • In the last 3 years, bioAffinity Technologies' Change in Accured Expenses had a median value of -$60,557 in 2023 and averaged $17,886.
  • As far as peak fluctuations go, bioAffinity Technologies' Change in Accured Expenses spiked by 2,110.59% in 2023, and later slumped by 476.22% in 2025.
  • Quarterly analysis of 4 years shows bioAffinity Technologies' Change in Accured Expenses stood at -$25,168 in 2022, then spiked by 2,110.59% to $506,025 in 2023, then decreased by 2.28% to $494,470 in 2024, then increased by 2.09% to -$63,487 in 2025.
  • Its Change in Accured Expenses stands at -$63,487 for Q3 2025, versus -$322,701 for Q2 2025 and -$27,987 for Q1 2025.